Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Chemotherapy response in ovarian cancer patients is frequently compromised by drug resistance, possibly due to altered drug metabolism. Platinum drugs are metabolised by glutathione S-transferase P1 (GSTP1), which is abundantly, but variably expressed in ovarian tumours. We have created novel ovarian tumour cell line models to investigate the extent to which differential GSTP1 expression influences chemosensitivity. METHODS: Glutathione S-transferase P1 was stably deleted in A2780 and expression significantly reduced in cisplatin-resistant A2780DPP cells using Mission shRNA constructs, and MTT assays used to compare chemosensitivity to chemotherapy drugs used to treat ovarian cancer. Differentially expressed genes in GSTP1 knockdown cells were identified by Illumina HT-12 expression arrays and qRT-PCR analysis, and altered pathways predicted by MetaCore (GeneGo) analysis. Cell cycle changes were assessed by FACS analysis of PI-labelled cells and invasion and migration compared in quantitative Boyden chamber-based assays. RESULTS: Glutathione S-transferase P1 knockdown selectively influenced cisplatin and carboplatin chemosensitivity (2.3- and 4.83-fold change in IC50, respectively). Cell cycle progression was unaffected, but cell invasion and migration was significantly reduced. We identified several novel GSTP1 target genes and candidate platinum chemotherapy response biomarkers. CONCLUSIONS: Glutathione S-transferase P1 has an important role in cisplatin and carboplatin metabolism in ovarian cancer cells. Inter-tumour differences in GSTP1 expression may therefore influence response to platinum-based chemotherapy in ovarian cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760 · cited 1×
“…mechanisms, including impaired DNA repair, decreased drug uptake, increased drug efflux and detoxification, have been proposed (reviewed by Galluzzi et al, 2012), we are still some way from understanding the molecular basis of drug resistance, and from developing biomarkers to predict the…”
Background
Cited by
Understanding and targeting resistance mechanisms in cancer
Lei, Z., Tian, Q., Teng, Q., Wurpel, J. N. D., Zeng, L., Pan, Y., & Chen, Z. (2023) · MedComm · doi:10.1002/mco2.265 · Cited by 347
Wang, Q., Bin, C., Xue, Q., Gao, Q., Huang, A., Wang, K., & Tang, N. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03718-4 · Cited by 308
Mechanisms of Taxane Resistance
Maloney, S., Spring, C., Morejon-Lasso, L., & Prosperi, J. (2020) · Cancers · doi:10.3390/cancers12113323 · Cited by 198
Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment
Schoutrop, E., Moyano-Galceran, L., Lheureux, S., Mattsson, J., Lehti, K., Dahlstrand, H., & Magalhaes, I. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.027 · Cited by 176
Zhang, W., Dai, J., Hou, G., Liu, H., Zheng, S., Wang, X., Lin, Q., Zhang, Y., Lu, M., Gong, Y., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.10.042 · Cited by 125
Molecular aspects of circadian pharmacology and relevance for cancer chronotherapy
Ozturk, N., Ozturk, D., Kavakli, I. H., & Okyar, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102168 · Cited by 106
“Circadian rhythms in phase II detoxification by GST contribute to toxicities of platinum complexes [123].”
BackgroundMicroRNAs and colorectal cancer chemoresistance: New solution for old problem
Vaghari-Tabari, M., Majidinia, M., Moein, S., Qujeq, D., Asemi, Z., Alemi, F., Mohamadzadeh, R., Targhazeh, N., Safa, A., & Yousefi, B. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118255 · Cited by 58
Metadata
- Authors
- Sawers, L., Ferguson, M. J., Ihrig, B. R., Young, H. C., Chakravarty, P., Wolf, C. R., & Smith, G.
- Venue
- British Journal of Cancer
- Published
- 2014-07-10
- Volume
- 111
- Issue
- 6
- Pages
- 1150-1158
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2062117097
- Cited by
- 126
- References
- 1
- FWCI
- 2.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.